Vivek Nagaraja

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Joshua J. Solomon, Sonye K. Danoff, Felix Woodhead et al. · The Lancet Respiratory Medicine · 2022 · 208 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment

Sicong Huang, Vanessa L. Kronzer, Paul F. Dellaripa et al. · Current Treatment Options in Rheumatology · 2020 · 73 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

Sara Jaafar, Alain Lescoat, Suiyuan Huang et al. · Arthritis Research & Therapy · 2021 · 69 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial

Cathie Spino, Richard McLain, Sindhu R. Johnson et al. · The Lancet Rheumatology · 2020 · 46 citations · Full text

Medicine, Dermatology, Pharmacotherapy +8

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Vivek Nagaraja, Cathie Spino, Erica Bush et al. · Arthritis Research & Therapy · 2019 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11